Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12months: the DALTECAN Study

Author(s):
Francis, C.W.; Kessler, C.M.; Goldhaber, S.Z.; Kovacs, M.J.; Monreal, M.; Huisman, M.V. (0000-0003-1423-5348); Bergqvist, D.; Turpie, A.G.; Ortel, T.L.; Spyropoulos, A.C.; Pabinger, I.; Kakkar, A.K.
Published
2015
Publication type
Article / Letter to editor
cancerdalteparindeep vein thrombosislow-molecular-weight heparinpulmonary embolismvenous thromboembolism
Date issued
2015-06-30
Language
English
Is part of
Journal of Thrombosis and Haemostasis (2015), Vol. 13, no. 6, p. 1028-1035
hdl
1887/100457
doi
10.1111/jth.12923